We’re delighted to announce the launch of our TruSight™ Oncology Comprehensive (EU), our newest CE-marked IVD test for Comprehensive Genomic Profiling (CGP). Pathologists and Oncologists can now benefit from end-to-end solution that:
With the high interest post our IVD roadmap update during ESMO, we’re hosting a VIP launch webinar event to introduce the benefits of the test, how Illumina supports customers with implementation, and our ongoing efforts towards market accessibly.
Find out more about our cutting edge, IVD solution, be part of the conversation, join us by registering to attend this event.
Your email address is never shared with third parties.